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Simple Summary: Metastasis is the main cause for cancer mortality. The most common metastatic 
sites of colorectal cancer (CRC) are the liver and lungs. Tumour-infiltrating lymphocytes are recog-
nized as beneficial prognostic factors both in primary and metastatic CRC, but less is known about 
their reciprocal differences. The aim of our study was to evaluate immune microenvironment and 
its prognostic value in a series of mismatch proficient (pMMR) CRC with matched liver and lung 
metastases. The proportion of tumours with high immune cell infiltration together with PD-L1-pos-
itivity almost doubled in metastases compared to primary tumours. Our study confirmed the prog-
nostic value of high ICS in least immune-infiltrated metastases in pMMR CRC patients. Major dif-
ferences observed in immune contexture between primary tumours and metastases may have sig-
nificance for treatment strategies for patients with advanced CRC. 
Abstract: Purpose: To evaluate immune cell infiltration, the programmed death-1/programmed 
death ligand-1 (PD-1/PD-L1) expression and their prognostic value in a series of mismatch profi-
cient (pMMR) CRC with matched liver and lung metastases. Methods: Formalin-fixed paraffin-em-
bedded tissue sections stained for CD3, CD8, PD-L1 and PD-1 from 113 primary CRC tumours with 
105 liver and 59 lung metastases were analyzed. The amount of CD3 and CD8 positive lymphocytes 
were combined as immune cell score (ICS). Comparative analyses on immune contexture were 
performed both between the primary tumour and matched metastases and between the meta-
static sites. Results: In liver metastases, immune cell infiltration was increased in general com-
pared to primary tumours but did not correlate case by case. On the contrary, ICS between 
lung metastases and primary tumours correlated well, but the expression of PD-1/PD-L1 was 
increased in lung metastases. The proportion of tumours with high ICS together with PD-L1-pos-
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itivity almost doubled in metastases (39%) compared to primary tumours (20%). High ICS (com-
pared to lowest) in patient’s least immune-infiltrated metastasis was an independent prognostic 
marker for disease-specific (HR 9.14, 95%CI 2.81–29.68) and overall survival (HR 6.95, 95%CI 2.30–
21.00). Conclusions: Our study confirms the prognostic value of high ICS in least immune-infil-
trated metastases in pMMR CRC patients. Major differences observed in immune contexture be-
tween primary tumours and metastases may have significance for treatment strategies for patients 
with advanced CRC.  
Keywords: colorectal cancer; metastases; tumour infiltrating lymphocytes; PD-1; PD-L1 
 
1. Introduction 
Colorectal cancer (CRC) is the third most common cancer worldwide and second in 
terms of cancer mortality [1,2]. The most common metastatic sites of CRC are the liver and 
lungs [3,4]. Approximately 15–25% of CRC patients have liver metastases at the time of 
primary diagnosis [5,6] and around equal number of patients will develop metastases 
within the next 5 years [7]. Lung metastases are found in about 10% of patients with newly 
diagnosed CRC and in 5% of patients within the next 5 years [8]. Five-year overall survival 
(OS) for CRC patients without metastasis at the diagnosis of the primary tumour is 75–
90%, whereas for patients with synchronous or metachronous metastases, the mean OS 
remains under 20% [9–11]. As the prognosis of patients with advanced CRC is dramati-
cally impaired, more effective therapeutic strategies are needed. Solitary and even multi-
ple metastases are increasingly within the limits of curative surgical treatment [6]. 
Immune escape is a notable hallmark of cancer [12]. Various subsets of immune cells 
are identified in tumour microenvironment, and they can either prevent tumour develop-
ment or promote tumour progression and metastasis [13]. The abundance of tumour-in-
filtrating lymphocytes (TILs) has been shown to have significant prognostic value both in 
local and advanced colorectal cancer [14–18]. Several studies have shown discordance in 
immune cell infiltration between primary tumour and metastases, but these studies have 
focused mainly on liver metastases, only [19,20]. The most frequent metastatic sites of 
CRC, liver and lung, are immunologically very different. Lung is an organ with a highly 
active local immune system (reviewed by [21]), whereas liver is considered as an immu-
nosuppressive organ [22]. How these immunological differences impact on response to 
recently generalized immune modulating therapies, is not currently known. 
About 15% of colorectal cancers are characterized by mismatch repair (MMR) defi-
ciency, leading to the generation of immunogenic neopeptides that enhance the anti-tu-
mour immune response. A promising response to immune checkpoint inhibitors has been 
seen in MMR-deficient solid tumours, regardless of their primary site [23,24], leading to 
them being approved by FDA, as a cancer group, an indication for immune checkpoint 
inhibitor treatment. However, the MMR-deficiency is infrequent in advanced CRC [25]. 
Nevertheless, an intensified immune infiltration has been associated with better survival 
also in metastatic CRC [26,27], but metastases and primary tumours have also been shown 
to differ regarding their immune infiltration [19,20]. 
Since the immune therapies are currently indicated only to be used for advanced 
CRC rather than non-metastatic CRC, the knowledge of immune contexture in metastases 
and whether it differs from the primary tumour may be essential for patient’s treatment. 
The present study aimed to clarify this question by analysing the surgically resected 
liver and lung metastases in a population-based, consecutive and thoroughly charac-
terized series of CRCs. We performed a quantification of immune cells and immune 
checkpoint (PD-1/PD-L1) expression in primary CRC tumour samples together with 
matched liver and lung metastases. Whole section slides were thoroughly analysed, and 
the results were related to patient’s clinical characteristics and survival. 




2.1. Patient Demographics 
A total of 1671 patients met the criteria of having been diagnosed and treated for CRC 
in the Central Finland Hospital District during the study period. Metastatic disease was 
diagnosed in 551 (33.0%), of which 296 (17.7%) had synchronous metastases. Of 1302 re-
sected Stage I-III patients, 255 (19.6%) developed metachronous metastases. The overall 
metastasectomy rate was 16.2% with synchronous metastases and 23.9% with metachro-
nous metastases [6]. Our study material included 113 CRC patients with operable liver 
and/or lung metastases operated at the Central Finland Central Hospital (CFCH) in 
Jyväskylä during the years 2000–2018. A total of 72 CRC patients with liver metastasis, 23 
patients with lung metastasis and 18 patients having both liver and lung metastasis were 
included in this study. Since some of the patients had several metachronous metastases, 
the total number of analysed liver and lung metastases was 105 and 59, respectively. 
The clinicopathological characteristics of the patients and the characteristics of me-
tastases are presented in Tables 1 and 2, respectively. The median age of patients at diag-
nosis of the primary tumour was 66 years and the age at onset was similar between the 
patients with liver and lung metastasis (p = 0.253). The stage of CRC at the time of the 
diagnosis was higher, whereas the tumour grade was lower in patients with liver metas-
tases (p < 0.001). There was no difference in the location of the primary tumour between 
colon and rectum in selection to metastasectomy. All patients undergoing resection for 
lung metastases only had recurrent disease (metachronous lung metastases) (p < 0.001). 
Preoperative chemotherapy as well as histological tumour response were more frequent 
with patients with liver metastases (p = 0.001 and 0.008, respectively). All primary tumours 
with resected liver or lung metastases within the 19-year study period were mismatch 
repair proficient (pMMR). 
Table 1. Cinicopathological variables in patients with metastatic colorectal cancer. 
Characteristics 
Location of Metastases 
Liver (% of Column) Lung (% of Column) Liver and Lung (% of Column) 
Total No of Patients 72 23 18 
Age    
<65 58 (81) 15 (65) 15 (83) 
≥65 14 (19) 8 (35) 3 (17) 
Gender    
Male 43 (60) 10 (44) 10 (56) 
Female 29 (40) 13 (56) 8 (44) 
Stage of disease    
I 3 (4) 0 3 (17) 
II 16 (22) 11 (48) 3 (17) 
III 14 (19) 12 (52) 4 (22) 
IV 39 (54) 0 8 (44) 
Primary tumour grade    
1 7 (10) 2 (9) 9 (50) 
2 56 (79) 16 (69) 8 (44) 
3 8 (11) 5 (22) 1 (6) 
Timing of metastases    
Synchronous 37 (51) 0 8 (44) 
Metachronous 35 (49) 23 10 (56) 
Primary tumour location    
Colon  51 (71) 11 (48) 11 (61) 
Rectum 21 (29) 12 (52) 7 (39) 
Metastases    
Mean no./patient (min-max) 2.1 (1–12) 1.6 (1–4) 3.4 (2–7) 
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Mean size (mm)/patient (min-
max)  
34 (7–105) 27 (7–90) 37 (15–70) 
Preoperative chemotherapy    
No 32 (44) 21 (91) 9 (50) 
Yes 40 (56) 2 (9) 9 (50) 
Survival after metastasectomy    
3-year DSS 43 (60) 11 (48) 13 (72) 
5-year DSS 37 (51) 7 (30) 10 (56) 
3-year OS 35 (49) 9 (39) 13 (72) 
5-year OS 28 (39) 5 (22) 8 (44) 
Abbreviations: DSS, disease specific survival; OS, overall survival. Primary tumour grade is missing from one patient with 
liver metastasis. 
2.2. Immune Contexture in Primary Colorectal Cancer and Matched Liver and Lung Metastases 
Figure 1 shows the representative IHC staining for CD3, CD8, PD-1 and PD-L1. The 
densities of CD3, CD8 and PD-1 lymphocytes in primary tumours and matched metasta-
ses (liver-only, lung-only and both) were analysed both in TC and IM and are shown in 
Figure 2. The density of TILs was higher in IM than in TC both in primary tumours and 
in metastases in all groups (Figure 2). CD3 and CD8 densities in IM were significantly 
higher in liver metastases compared to primary tumours (p < 0.001). This was seen also in 
patients having both liver and lung metastases (p < 0.001). Instead, the density of TILs did 
not differ between lung metastases and corresponding primary tumours. Compared to 
lung metastases, CD8 density in IM was significantly higher in liver metastases (p = 0.005, 
Table 2). 
 
Figure 1. Immunohistohistochemical staining of CD3, CD8, PD-1 and PD-L1 in primary colorectal tumour. Figures (A,B) 
show representative immunostaining of high infiltrates of CD3 (A) and CD8 lymphocytes (B), respectively. Figures (C,D) 
show representative immunostaining of high PD-1 expression (C) and strong expression of PD-L1 in immune cells (D) 
surrounding the tumour area (10× magnification, scale bar 250 µm). 




Figure 2. Box plot of immune cell densities in primary tumours and matched metastases in patients with liver-only, liver 
and lung and lung-only metastases. Horizontal line indicates the median, box the interquartile range (IQR) and whiskers 
the smallest/largest value no further than 1.5 × IQR. Abbreviations: TC: tumour center; IM: invasive margin. 
Table 2. Metastases’ characteristics. 
Total Number of 
Metastases 
Liver Metastases (% of Column) Lung Metastases (% of Column) p-Value 
105 59  
Primary tumor location  
colon 73 (70) 28 (55) 
0.005 
rectum 32 (30) 31 (45) 
Mean size (mm) 34.5 31.4 0.148 
Timing of metastases  
Synchronous 56 (53) 11 (19) 
<0.001 
Metachronous 49 (47) 48 (81) 
Preoperative chemotherapy  
No 45 (43) 44 (75) <0.001 
Yes 60 (57) 15 (25)  
Tumour regression grade  
1–2 (MjHR) 8 (13) 1 (7)  
3 (PHR) 25 (42) 3 (20) 0.146 
4–5 (NHR) 27 (45) 11 (73)  
TILs density *   
CD3 TC 504 ± 537 651 ± 535 0.334 
CD3 IM 2098 ± 877 1596 ± 926 0.269 
CD8 TC 219 ± 272 223 ± 248 0.232 
CD8 IM 894 ± 483 438 ± 374 0.005 
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PD-1 TC 19 ± 34 41 ± 67 0.001 
PD-1 IM 53 ± 62 79 ± 116 0.003 
Immune cell score   
0 18 (18) 12 (22) 
0.230 
1 13 (13) 7 (13) 
2 21 (21) 19 (34) 
3 13 (13) 6 (11) 
4 35 (35) 11 (20) 
PD-L1 TC    
neg 102 (98) 56 (95) 
0.261 
pos 2 (2) 3 (5) 
PD-L1 IC    
neg 49 (47) 12 (20) 
0.001 
pos 55 (53) 47 (80) 
Abbreviations: MjHR, major or complete histological tumour response; PHR, partial histological tumour response, NHR, 
no histological tumour response; TILs, tumour infiltrating lymphocytes; PD-1, programmed cell death protein 1; PD-L1, 
programmed death ligand 1; TC, tumour cell; IM, invasive margin; IC, immune cell; *, cells per 1 mm2. ICS was indeter-
minable from five liver and four lung metastases and PD-L1 from one liver metastasis. 
The density of PD-1 positive cells was significantly higher in IM of lung metastases 
compared to corresponding primary tumours (p = 0.034, Figure 2). Compared to liver me-
tastases, PD-1 density in TC and IM was significantly higher in lung metastases (p = 0.001 
and 0.003, respectively, Table 2). Categorized immune variables in primary tumours and 
matched metastases are shown in Supplementary Materials Table S1. PD-L1 expression 
was mainly found on immune cells rather than on tumour cells both in primary tumours 
and in metastases. PD-L1 positive tumour cells were only found in one primary tumour, 
in two liver metastases and in three lung metastases. By contrast, PD-L1 expression on 
immune cells (IC), principally determining the PD-L1 positivity, was commonly seen both 
in primary tumours and in metastases. PD-L1 expression was significantly higher in lung 
metastases compared to both primary tumours (p < 0.001, Table S1) and liver metastases 
(p = 0.001, Table 2). When the immune cell densities were compared according to the time 
of appearance of metastases, less CD3 and CD8 lymphocytes in TC (p = 0.005 and <0.001, 
respectively) were found in metachronous compared to synchronous metastases. No dif-
ferences in PD-1 density or PD-L1 positivity were seen between these groups.  
We also analysed correlations between immune infiltrates in primary tumours and 
matched metastases. In patients with lung metastases, CD3 in TC (r = 0.365, p = 0.006) and 
in IM (r = 0.395, p = 0.004) as well as CD8 in TC (r = 0.349, p = 0.008) and in IM (r = 0.455, p 
= 0.001) all moderately correlated with CD8 density of IM in corresponding primary tu-
mours. In addition, PD-1 in TC and IM in lung metastases moderately correlated with PD-
1 in TC of primary tumours (r = 0.314, p = 0.018 and r = 0.404, p = 0.003, respectively). Also, 
PD-L1 in IC correlated between lung metastases and primary tumours (r = 0.338, p = 0.011). 
In patients with liver metastases, neither TILs nor PD-1/PD-L1 correlated between pri-
mary tumours and metastases (Figure 3).  




Figure 3. Correlograms of T cell densities in colorectal adenocarcinomas and their metastases ((A): Liver; (B): Lung). The 
numbers indicate Spearman’s rank correlation coefficients. Abbreviations: IM: invasive margin; prim: primary tumour; 
met: metastasis; TC: tumour center. 
ICS was more often high in liver metastases compared to primary tumours (p = 0.025, 
Table S1). Immunoprofiles differed significantly both in liver and lung metastases com-
pared to their primary tumours (p = 0.045 and 0.009, respectively, Table S1). Altogether, 
ICS strongly associated with the density of PD-1 positive cells and PD-L1 positivity both 
in primary tumours and metastases. When individual immune parameters were com-
bined into a Tumour Immunity in the MicroEnvironment (TIME) classification (Figure 4), 
remarkable differences between primary tumours and metastases were seen (p < 0.001). 
The proportion of high immune cell infiltration (TIME2 and TIME3) was higher in metas-
tases (49.7%) compared to primary tumours (33.4%) (p = 0.008). Furthermore, the propor-
tion of cancers with presence of PD-L1 together with high immune cell infiltration 
(TIME2) almost doubled in metastases (39.4%) compared to primary tumours (20.4%) (p = 
0.008). TIME subtypes either in primary tumours or in metastases did not associate with 
DSS or OS.  
 
Figure 4. TIME classification of primary tumours and metastases. Subtypes are immunological ignorance; T1 
(ICSlowPDL1neg), adaptive immune resistance; T2 (ICShighPDL1pos), tolerance; T3 (ICShighPDL1neg) and intrinsic in-
duction; T4 (ICSlowPDL1pos). The values represent the percentage of each subtype. (ICS = Immune Cell Score). 
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Metastatic immune densities were also studied in relation with the response to pre-
operative treatment. ICS was more frequently high in metastases with histological tumour 
response (TRGs 1–3) compared with the metastasis having no response (TRGs 4–5) (87% 
vs. 63%, p = 0.003). Differences were not seen in PD-1 or PD-L1 positivity between re-
sponse-based groups.  
2.3. Prognostic Impact of Immune Contexture in Primary Tumours and Metastases 
Since primary tumour resection, the mean survival time of patients with operated 
liver, lung and both metastases were 5.0 ± 3.7, 6.4 ± 4.1 and 5.4 ± 2.4 years, respectively (p 
= 0.362). Time between primary tumour resection and the first metachronous metastasis 
was 1.1 ± 1.2, 2.5 ± 1.4 and 1.0 ± 1.1 years, respectively (p < 0.001). There were no cases with 
operated synchronous lung metastases. CRC was the cause of death in 57% of patients. 
Three- and 5-year DSS rates after metastasectomy were 60% and 51%, 48% and 30%, and 
72% and 56% for patients with liver, lung and both metastases, respectively. Accordingly, 
3- and 5-year OS rates after metastasectomy were 49% and 39%, 39% and 22% and 72% 
and 44%, respectively (Table 1). 
Figure 5 shows Kaplan-Meier curves for the entire cohort (OS and DSS, Figure 5A) 
and Forest Plots showing subgroup results (Figure 5B). Among the analysed clinicopatho-
logical variables, high TNM stage of primary disease was prognostic for poor survival, 
with stage IV having 40% 5-year DSS and 34% 5-year OS (p = 0.011 and 0.006, respectively). 
The survival of patients with metachronous metastases was better compared to patients 
with synchronous metastases, with 62% 5-year DSS and 55% 5-year OS (p = 0.021 and 
0.020, respectively). Among immune variables, high ICS of the patient’s least-infiltrated 
metastasis (Figure 6) was significantly prognostic for better survival outcome, with 5-year 
DSS of 17% for ICS0 versus 63% for ICS4 as well as 5-year OS of 17% for ICS0 versus 55% 
for ICS4 (p = 0.001 and 0.002, respectively).  
According to the univariable analysis, stage of primary disease, primary tumour 
grade, onset of metastases, primary tumour location, size of metastases, ICS and PD-L1IC 
were included in the multivariable analysis together with age and sex. Table 3 shows the 
multivariable model with separate immune parameters for ICS and PD-L1IC. ICS of pa-
tient’s least-infiltrated metastasis was found to be an independent prognostic marker. 
ICS0, with respect to ICS4 as a reference, had a DSS hazard ratio (HR) of 9.14 and an OS 
HR of 6.95 (p < 0.001 and 0.001, respectively). High stage of primary disease was prognos-
tic for worse OS (HS 9.44, p = 0.045) and high grade of primary tumour for worse DSS (HR 
4.18, p = 0.035). Furthermore, rectal tumour location had a worse DSS (HR 2.19, p = 0.008). 
Combining ICS, PD-1 and PD-L1 as immunoprofile in metastases did not enhance the 
prognostic performance.  




Figure 5. Kaplan-Meier curves for the entire cohort (OS and DSS) (A) and Forest plots for subgroup results (B). 
  




Figure 6. Disease-specific and overall survival according to ICS 0–4, PD-1, PD-L1IC and immunoprofile of least-infiltrated 
metastases. 
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Table 3. Multivariable analysis with Cox proportional hazard model. 
Characteristics 
Univariable Analysis 





HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value 
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PD-L1 IC         
low 1.55  0.192 1.33  0.382 1.60  0.290 1.55  0.298 
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(0.80–2.97) (0.70–2.55) (0.67–3.79) (0.68–3.50) 
high 1 1 1 1 
Abbreviations: DSS, disease-specific survival; OS, overall survival HR, hazard ratio; CI, confidence interval; PD-1, pro-
grammed cell death protein 1; PD-L1, programmed death ligand 1; IC, immune cell. Analyses were performed with the 
following reference categories: <65 years, male gender, TNM Stage I-II, tumour grade 1, metachronous onset of metastases, 
tumour location in colon, size of metastases <29 mm, high Immune cell score, and high PD-L1IC. For analyses, 110 patients 
were available. One patient had unknown primary tumour grade, size of metastases was missing from one patient and 
PD-L1IC was indeterminable from two patients. 
3. Discussion 
We studied a reasonable number of liver and lung metastases together with primary 
tumours from mismatch repair proficient (pMMR) patients to expand the knowledge of 
immune microenvironment in these tumours. Immune cell infiltration in liver metastases 
was increased but did not correlate with TIL density of the corresponding primary tu-
mours. In lung metastases, the number of TILs moderately correlated with the density in 
primary tumours, and PD-1 and PD-L1 expressions were increased in lung metastases 
compared to primary tumours. Furthermore, the proportion of tumours with high im-
mune cell infiltration together with PD-L1-positivity almost doubled in metastases com-
pared to primary tumours. In this study cohort, high ICS in patient’s least-infiltrated me-
tastasis was proven to have prognostic value in pMMR CRC patients. 
Multiple data support the major role of immune infiltrates within primary CRC tu-
mours in predicting the survival of patients [16–18,28]. Increasing evidence also exist on 
the positive impact of intrametastatic immune infiltrates on patients with advanced CRC 
[27,29,30] as well as their response to chemotherapy [26]. Our results confirm the previous 
observation that ICS in the least immune-infiltrated metastases has prognostic value 
[27,30]. However, the density of PD-1 positive cells and PD-L1 positivity did not increase 
the prognostic value of ICS, which was previously seen with primary CRC and small 
bowel adenocarcinomas [31,32]. Still, these immune factors were strongly associated with 
each other also in metastases.  
Few publications have reported a comparison of immune microenvironment be-
tween CRC metastases and corresponding primary tumours. Previous studies have 
shown that liver metastases of CRC differ from primary tumours [15,19,30]. Metastases of 
the same patient have also diverse amounts of immune cells [27,30,33]. Lung metastases 
in CRC are less studied with discordant results [34,35]. Our study shows a few interesting 
differences between lung and liver metastases. Equally to previous studies [27,30,35], but 
in contrast to the study by Remark et al. [34], the density of TILs was higher in both liver 
and lung metastases compared to primary tumours. Interestingly, immune cell infiltration 
in liver metastases was increased in general compared to primary tumours, but not in case 
by case and PD-1/PD-L1 expression was increased only in lung metastases. It is plausible 
that the less adapted tumour microenvironment of the metastatic sites recruits more host 
immune cells attracted by the unidentified cancer cells than that of the primary tumour 
site. Recently, specific changes in cancer-related genes and immune cell infiltration in CRC 
metastases have been related to metastatic evolution, which produce new perspectives for 
cancer diagnostics and therapeutic strategies [36,37]. 
Immunotherapy has been demonstrated to benefit some patients with mismatch re-
pair deficient (dMMR) CRC [38,39]. Presumably, this results from high mutation burden 
due to the defective DNA mismatch repair and the following high neoantigen density, 
which primes T-cells to strong antitumour immune responses [40,41]. TIME classification 
has been proposed as a frameshift for tailoring cancer immunotherapy [42,43]. Recently, 
the associations between TIME subtypes and clinical, pathological, and molecular charac-
teristics of CRC were studied [44]. Among other characteristics, TIL-present subtypes 
(TIME 2 and 3); the proposed candidates for immunotherapy, were associated with 
dMMR. However, stage 4 dMMR tumours constitute only 4% of all advanced CRCs [45]. 
For the vast majority of advanced CRC that are pMMR, alternative treatment approaches 
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are needed. In our study cohort, there was no case of metastatic dMMR CRC which 
demonstrates the difference in the behaviour between dMMR and pMMR CRC. dMMR 
CRC seems to be less capable to develop distant metastases. To our knowledge, this is the 
first study showing the distribution of TIME subgroups between primary CRC tumours 
and metastases. Our results show that the proportion of tumours potentially responsive 
to immunotherapy is highly increased in metastases compared to primary tumours in 
pMMR CRC patients. Essential changes in immune pattern seem to occur during the pro-
gress of CRC that should not be ignored, when tailoring the treatment for patients with 
advanced CRC. However, combination strategies are apparently needed for improving 
treatment efficacy in pMMR CRC [46]. 
Our study has some limitations. The number of patients with resected metastases is 
relatively small and inclusion of only resectable patients may subject to selection bias. 
However, the studied patients belong to a well-characterized population-based cohort of 
patients with CRC (n = 1671) in Central Finland in 2000–2015 with comprehensive follow-
up and reliable cancer recurrence and survival data[6]. Strength of our study is the evalu-
ation of metastatic immune infiltration from whole tumour sections. As shown previously 
[30], biopsy or a TMA core of a metastasis rarely represents the whole lesion, due to the 
intra- and inter-tumour heterogeneity of immune infiltrates. The evaluation of PD-L1 ex-
pression from biopsies has been shown even more unreliable [30]. Overall, our results 
highlight the importance of studing the immune contexture also in metastases in addition 
to primary tumour in advanced CRC. 
4. Materials and Methods 
4.1. Tumour Sampling 
All patients diagnosed with primary CRC during years 2000–2016 were identified 
using the histopathological registry of the Central Finland Central hospital, which covers 
all CRCs diagnosed in the Central Finland area (population catchment area of approxi-
mately 280,000). All patients with metastasectomy of liver or lung were included and only 
operated metastases are involved in the tables. 
In cases of a metachronous CRC or a local recurrence, the analyses were performed 
on the patient´s first CRC sample. The metastases were classified synchronous, if diag-
nosed at the same time or before the primary tumour, and metachronous, if diagnosed in 
the postoperative surveillance. Cancer progression and survival of the patients were fol-
lowed until the censoring date end of June 2020. Causes of death were updated in June 
2020 from the Finnish Cause of Death Registry. The examination of the primary CRC and 
metastasis tissue was performed by a pathologist following the AJCC guidelines (8th edi-
tion). Tumour samples were graded (grades 1–4) based on the percentage of glandular 
formation according to the World Health Organization (WHO) criteria [44]. 
4.2. Immunohistochemical Analyses 
Both the 113 primary CRC tumours with 105 liver and 59 lung metastases were in-
cluded in analogous immunohistochemical analyses. Formalin-fixed paraffin-embedded 
whole tissue sections of 3 µm thickness were used. Mismatch repair status was deter-
mined by immunohistochemical analysis for the expression of MLH1, PMS2, MSH2, and 
MSH6 as described previously [47]. Staining for PD-1 (The Human Genome Organization 
(HUGO) name PDCD1) and PD-L1 (HUGO name CD274) was conducted with anti-
PDCD1 (SP269, 1:50; Spring Bioscience, Pleasanton, CA, USA) and anti-CD274 (E1L3N, 
1:100; Cell Signaling Technology, Danvers, MA, USA) antibodies, using a BOND-III 
stainer (Leica Biosystems, Buffalo Grove, IL, USA). Staining for CD3 and CD8 was con-
ducted with anti-CD3 (LN 10, 1:200; Leica Biosystems, Newcastle, UK) and anti-CD8 
(SP16, 1:400; Thermo Scientific, Fremont, CA, USA) antibodies, using a Lab Vision Auto-
stainer 480 (ImmunoVision Technologies Inc., Brisbane, CA, USA). Signal visualization 
was done by diaminobenzidine and sections were counterstained with haematoxylin. 
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Slides were scanned with a NanoZoomer-XR (Hamamatsu Photonics, Hertfordshire, UK) 
at ×20 magnification. 
4.3. Scoring 
Scoring was conducted as described earlier [31], and both primary tumours and me-
tastases were analysed similarly. Briefly, positively stained CD8, CD3 and PD-1 lympho-
cytes (per 1 mm2) were calculated from the representative areas of tumour centre and in-
vasion margin by using QuPath [48]. The invasive margin was selected manually using 
an annotation brush with a diameter of 720 µm [49]. The mean analysed area from CD3, 
CD8- and PD-1-stained sections was 36 mm2. Cut-off values for ICS were selected from 
receiver operating characteristic curves (815 for CD3+ and 384 for CD8+ in the tumour 
centre (TC) and 1144 for CD3+ and 496 for CD8+ in the invasive front (IM) of primary 
tumours (Rajamäki K. (University of Helsinki, Helsinki, Finland). Personal communica-
tion, 2020), and 94 for CD3+ and 33 for CD8+ in the TC and 1322 for CD3+ and 664 for 
CD8+ in the IM of metastases) in relation to disease-specific 3-year mortality. Accordingly, 
cut-off value for PD-1 positivity was selected from receiver operating characteristic curve 
(15 positive cells per mm2 in primary tumours and 27 in metastases).  
ICS was formulated following the example of Galon et al. [28], as presented in our 
previous studies [18,31]. Patients were divided into low ICS (scores 0–2) and high ICS 
(scores 3–4) groups for further analysis. The impact of immune cell densities on survival 
was analysed from the metastasis with the smallest number of immune cells called least-
infiltrated metastasis. Tumour samples were also categorized into four different TIME-
classes  [42] based on the presence of TILs (ICS low/high) and PD-L1 expression (PD-L1 
positivity/negativity). 
PD-L1 expression was evaluated on tumour cells (TC) and tumour infiltrating im-
mune cells (IC) throughout the TC and IM as described previously [31]. Both the percent-
age of stained tumour cells and immune cells and the staining intensity were visually es-
timated. Tumour sample was defined as PD-L1 positive when ≥5% of the tumour cells 
and/or tumour infiltrating immune cells was positive for PD-L1 with moderate or strong 
intensity. 
Tumour regression was scored for each metastasis according to the scheme of Rub-
bia-Brandt [50], where the tumour regression grades (TRGs) 1–5 are based on the presence 
of residual tumour cells and the extent of fibrosis. Five TRGs were further categorized into 
three groups: major or complete histological tumour response (MjHR; TRG1 and TRG2), 
partial histological tumour response (PHR; TRG 3) and no histological tumour response 
(NHR; TRG 4 and TRG5). 
4.4. Statistical Analysis 
Categorical data were compared using the Pearson’s chi-square test. The Kaplan-
Meier method was used to calculate disease-specific survival (DSS) and overall survival 
(OS), and the log-rank test was used to compare differences. Survival times for DSS and 
OS were calculated from the date of primary surgery to the date of death or the end of 
follow-up. Death within 30 days following surgery was considered postoperative. Uni-
variable and multivariable Cox proportional hazards regression models were used to an-
alyse prognostic factors for DSS and OS. Only variables with a p value of < 0.20 in univar-
iable analysis were included in the multivariable analysis with age and sex. Statistical 
analysis was performed using IBM SPSS Statistics (version 23.0; SPSS Inc., Chicago, IL, 
USA). 
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4.5. Ethical Aspects  
The study was approved by the ethical committee of the Central Finland Central 
Hospital and the National Supervisory Authority for Welfare and Health (Valvira, Hel-
sinki, Finland). 
5. Conclusions 
In conclusion, our study shows differences in immune contexture between primary 
tumours and matched metastases in advanced CRC. The proportion of tumours with high 
immune cell infiltration together with PD-L1-positivity almost doubled in metastases 
compared to primary tumours. Our study also confirms that high ICS in patient’s least-
infiltrated metastasis has prognostic value in pMMR CRC patients. 
Major differences observed in the immune environment of the primary tumour and 
metastatic sites reflect the immune-avoiding capabilities acquired by the migrant tumour 
cell population and the tumour-benefiting circumstances of tumour microenvironment 
allowing the metastatic tumorigenesis. These differences may be somewhat stochastic, but 
common denominators of the immune cell densities were revealed by our well-validated 
quantification tools. The characteristics and trends identified in the current study may 
help in designing anti-cancer therapy schemas that make the most out of the host immune 
response performance and enable further work in identifying which patients in the 
pMMR subcohorts might benefit from immunomodulative treatment options. 
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